236 related articles for article (PubMed ID: 20124184)
1. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.
Dunbier AK; Anderson H; Ghazoui Z; Folkerd EJ; A'hern R; Crowder RJ; Hoog J; Smith IE; Osin P; Nerurkar A; Parker JS; Perou CM; Ellis MJ; Dowsett M
J Clin Oncol; 2010 Mar; 28(7):1161-7. PubMed ID: 20124184
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
3. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Madeira M; Mattar A; Logullo AF; Soares FA; Gebrim LH
BMC Cancer; 2013 Sep; 13():425. PubMed ID: 24047421
[TBL] [Abstract][Full Text] [Related]
5. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.
Geisler J; Detre S; Berntsen H; Ottestad L; Lindtjørn B; Dowsett M; Einstein Lønning P
Clin Cancer Res; 2001 May; 7(5):1230-6. PubMed ID: 11350888
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
Weigel MT; Ghazoui Z; Dunbier A; Pancholi S; Dowsett M; Martin LA
Breast Cancer Res; 2012 May; 14(3):R78. PubMed ID: 22608253
[TBL] [Abstract][Full Text] [Related]
7. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
8. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Folkerd EJ; Dixon JM; Renshaw L; A'Hern RP; Dowsett M
J Clin Oncol; 2012 Aug; 30(24):2977-80. PubMed ID: 22802308
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA
J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689
[TBL] [Abstract][Full Text] [Related]
10. Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.
Kurosumi M; Takatsuka Y; Watanabe T; Imoto S; Inaji H; Tsuda H; Akiyama F; Sakamoto G; Ikeda T; Noguchi S
J Cancer Res Clin Oncol; 2008 Jun; 134(6):715-22. PubMed ID: 18075758
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Dunbier AK; Ghazoui Z; Anderson H; Salter J; Nerurkar A; Osin P; A'hern R; Miller WR; Smith IE; Dowsett M
Clin Cancer Res; 2013 May; 19(10):2775-86. PubMed ID: 23493347
[TBL] [Abstract][Full Text] [Related]
12. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.
Kyvernitakis I; Knöll D; Struck M; Hars O; Bauer T; Hadji P
J Cancer Res Clin Oncol; 2014 Jan; 140(1):159-66. PubMed ID: 24292402
[TBL] [Abstract][Full Text] [Related]
13. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
14. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
[TBL] [Abstract][Full Text] [Related]
15. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
Murray J; Young OE; Renshaw L; White S; Williams L; Evans DB; Thomas JS; Dowsett M; Dixon JM
Breast Cancer Res Treat; 2009 Apr; 114(3):495-501. PubMed ID: 18438705
[TBL] [Abstract][Full Text] [Related]
16. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
17. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
18. Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer.
Flågeng MH; Knappskog S; Gjerde J; Lønning PE; Mellgren G
PLoS One; 2015; 10(8):e0134351. PubMed ID: 26247365
[TBL] [Abstract][Full Text] [Related]
19. Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer.
Haynes BP; Viale G; Galimberti V; Rotmensz N; Gibelli B; A'Hern R; Smith IE; Dowsett M
Breast Cancer Res Treat; 2013 Feb; 138(1):157-65. PubMed ID: 23378065
[TBL] [Abstract][Full Text] [Related]
20. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.
Ingle JN; Kalari KR; Buzdar AU; Robson ME; Goetz MP; Desta Z; Barman P; Dudenkov TT; Northfelt DW; Perez EA; Flockhart DA; Williard CV; Wang L; Weinshilboum RM
Steroids; 2015 Jul; 99(Pt A):32-8. PubMed ID: 25163006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
